Vimarsana
Biggest News Aggregation in the World

Page 21 - Looking Information News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Looking Information. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Looking Information Today - Breaking & Trending Today

TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer - Vimarsana News

TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer

Company Announcement Full approval based on global Phase 3 study demonstrating overall survival benefit of TIVDAK compared to chemotherapyTIVDAK is the first antibody-drug conjugate in this patient...

ARCPOINT TO HOST CONFERENCE CALL TO DISCUSS 2023 Q4 AND FULL YEAR FINANCIAL RESULTS - Vimarsana News

ARCPOINT TO HOST CONFERENCE CALL TO DISCUSS 2023 Q4 AND FULL YEAR FINANCIAL RESULTS

Greenville, South Carolina, April 29, 2024 -- ARCpoint Inc. a leading US-based franchise system providing drug testing, alcohol screening, DNA and direct to consumer clinical lab testing...

Pfizer Highlights Progress in Accelerating Breakthrough Cancer Medicines at ASCO 2024 Annual Meeting - Vimarsana News

Pfizer Highlights Progress in Accelerating Breakthrough Cancer Medicines at ASCO 2024 Annual Meeting

NEW YORK--(BUSINESS WIRE)--Apr 29, 2024--

SOUTHERN MISSOURI BANCORP REPORTS PRELIMINARY RESULTS FOR THIRD QUARTER OF FISCAL 2024; DECLARES QUARTERLY DIVIDEND OF $0.21 PER COMMON SHARE; CONFERENCE CALL SCHEDULED FOR TUESDAY, APRIL 30, AT 9:30AM CENTRAL TIME - Vimarsana News

SOUTHERN MISSOURI BANCORP REPORTS PRELIMINARY RESULTS FOR THIRD QUARTER OF FISCAL 2024; DECLARES QUARTERLY DIVIDEND OF $0.21 PER COMMON SHARE; CONFERENCE CALL SCHEDULED FOR TUESDAY, APRIL 30, AT 9:30AM CENTRAL TIME

Poplar Bluff, Missouri, April 29, 2024 -- Southern Missouri Bancorp, Inc. , the parent corporation of Southern Bank , today announced preliminary net income for the third quarter of fiscal 2024...

TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer - Vimarsana News

TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer

Company Announcement Full approval based on global Phase 3 study demonstrating overall survival benefit of TIVDAK compared to chemotherapy TIVDAK is the first antibody-drug conjugate in this...